決奈達(dá)隆雜質(zhì)，艾曲波帕雜質(zhì)對(duì)照品  產(chǎn)品介紹：
中文名稱： 決奈達(dá)隆雜質(zhì)，艾曲波帕雜質(zhì)對(duì)照品 
英文名稱：
規(guī)格：10mg/25mg/50mg/100mg等多種規(guī)格可選。
用途：實(shí)驗(yàn)研發(fā)，藥品申報(bào)檢測(cè)，不得用于臨床醫(yī)學(xué)診斷。
隨貨提供：所有雜質(zhì)對(duì)照品均隨貨提供HPLC，NMR，MS圖譜及CoA證書。
保存及取用：為了防止產(chǎn)品含量降低，應(yīng)防潮，避光和抗氧化包裝，保存應(yīng)以提高物質(zhì)穩(wěn)定性為原則。如果一次使用很少量，可以將其適當(dāng)分裝后使用，這樣可以有效的防止試劑污染。請(qǐng)不要在臟亂和強(qiáng)光環(huán)境中取用，以免造成污染和失效。

 決奈達(dá)隆雜質(zhì)，艾曲波帕雜質(zhì)對(duì)照品 雜質(zhì)列表：

Dronedarone	N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)benzofuran-5-yl)methanesulfonamide
Dronedarone Impurity 1	N-(3-(4-(3-aminopropoxy)benzoyl)-2-butylbenzofuran-5-yl)methanesulfonamide hydrochloride
Dronedarone Impurity 2	N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)benzofuran-5-yl)formamide hydrochloride
Dronedarone Impurity 3	N-butyl-N-(3-(4-(2-butyl-5-(methylsulfonamido)benzofuran-3-carbonyl)phenoxy)propyl)butan-1-amine oxide
Dronedarone Impurity 4	N-[2-Butyl-3-[4-[3-(butylamino)propoxy]benzoyl]-5-benzofuranyl]methanesulfonamide hydrochloride
Dronedarone Impurity 5	(5-amino-2-butylbenzofuran-3-yl)(4-(3-(dibutylamino)propoxy)phenyl)methanone methanone dioxalate
Dronedarone Impurity 6	(5-amino-2-butylbenzofuran-3-yl)(4-hydroxyphenyl)methanone
Dronedarone Impurity 7	(2-butyl-5-nitrobenzofuran-3-yl)(4-hydroxyphenyl)methanone
Dronedarone Impurity 8	N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)benzofuran-5-yl)-N-(methylsulfonyl)methanesulfonamide hydrochloride
Dronedarone Impurity 9	(2-butyl-5-nitrobenzofuran-3-yl)(4-methoxyphenyl)methanone
Dronedarone Impurity 10	(5-amino-2-butylbenzofuran-3-yl)(4-(3-aminopropoxy)phenyl)methanone
Dronedarone Impurity 11	(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)benzofuran-5-yl)sulfamoyl chloride hydrochloride
Dronedarone Impurity 12	N,N'-(3,3'-(4,4'-(propane-1,3-diylbis(oxy))bis(benzoyl))bis(2-butylbenzofuran-5,3-diyl))dimethanesulfonamide
Dronedarone Impurity 13	Methyl 2-(2-forMyl-4-nitrophenoxy)hexanoate
Dronedarone Impurity 14	2-(2-forMyl-4-nitrophenoxy)hexanoic acid
Eltrombopag	(Z)-3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid
Eltrombopag Impurity 1	5'-chloro-2'-hydroxy-3'-nitro-[1,1'-biphenyl]-3-carboxylic acid
Eltrombopag Impurity 2	3'-amino-5'-chloro-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid
Eltrombopag Impurity 3	3'-amino-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid
Eltrombopag Impurity 4	1-(3,4-dimethylphenyl)-3-methyl-1H-pyrazol-5(4H)-one
Eltrombopag Impurity 5	1-(3,4-dimethylphenyl)-4-(hydroxyamino)-3-methyl-1H-pyrazol-5(4H)-one
Eltrombopag Impurity 6	(E)-1-(3,4-dimethylphenyl)-4-(hydroxyimino)-3-methyl-1H-pyrazol-5(4H)-one
Eltrombopag Impurity 7	(Z)-5'-chloro-3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid
Eltrombopag Impurity 8	5',5''-bis((Z)-2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-4'',6'-dihydroxy-[1,1':3',1'':3'',1'''-quaterphenyl]-3,3'''-dicarboxylic acid
Eltrombopag Impurity 9	(Z)-ethyl 3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylate
Eltrombopag Impurity 10	1',2-bis(3,4-dimethylphenyl)-3-hydroxy-3',5-dimethyl-3,4-dihydro-1'H,2H-[3,4'-bipyrazol]-5'(4'H)-one
Eltrombopag Impurity 11	(2R,3R,4R,5S,6R)-6-((3'-((Z)-2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)-1-hydroxyhydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carbonyl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid
Eltrombopag Impurity 12	3'-acetamido-2'-(((3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-[1,1'-biphenyl]-3-carboxylic acid
Eltrombopag Impurity 13	(Z)-3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxamide
Eltrombopag Impurity 14	(Z)-methyl 3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylate
Eltrombopag Impurity 15	(E)-5'-chloro-3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)-1-hydroxyhydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid
Eltrombopag Impurity 16	1-(4-ethoxyphenyl)-5-(2-hydroxy-4-methoxybenzoyl)pyridin-2(1H)-one
Eltrombopag Impurity 17	(Z)-3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2'-methoxy-[1,1'-biphenyl]-3-carboxylic acid

若雜質(zhì)列表中未有您需要的雜質(zhì)，歡迎來電或在線詳詢，產(chǎn)品庫時(shí)常會(huì)有更新，另外，我司有專業(yè)研發(fā)團(tuán)隊(duì)，可提供部分雜質(zhì)定制服務(wù)，以最大可能的滿足您對(duì)雜質(zhì)對(duì)照品的選購需求。

 決奈達(dá)隆雜質(zhì)，艾曲波帕雜質(zhì)對(duì)照品 訂購方式：
聯(lián)系人：何先生
手機(jī)：15012456311
QQ：781007885
郵箱：phastandards@gmail.com
歡迎您通過電話，電郵或在線客服向我司詢價(jià)及訂購產(chǎn)品。

 決奈達(dá)隆雜質(zhì)，艾曲波帕雜質(zhì)對(duì)照品 作用機(jī)理：
 日前，美國(guó) FDA 批準(zhǔn)葛蘭素史克艾曲波帕 (Eltrombopag) 補(bǔ)充新藥申請(qǐng)(sNDA)，用于對(duì)免疫抑制療法(IST) 沒有充分響應(yīng)的嚴(yán)重型再生障礙性貧血 (SAA) 患者治療。艾曲波帕是一種促血小板生成素 (TPO) 受體激動(dòng)劑，為了增加血細(xì)胞的產(chǎn)生，日服一次艾曲波帕?xí)椭T導(dǎo)骨髓干細(xì)胞的增殖和分化。

 決奈達(dá)隆雜質(zhì)，艾曲波帕雜質(zhì)對(duì)照品  深圳遠(yuǎn)揚(yáng)專注醫(yī)藥標(biāo)準(zhǔn)品，雜質(zhì)對(duì)照品，更多產(chǎn)品，歡迎選購（篇幅有限，只列舉了一小部分，更多更全，請(qǐng)來電詳詢）：
雜質(zhì)對(duì)照品部分產(chǎn)品列表：
多西他賽雜質(zhì)，阿司咪唑雜質(zhì)，硝呋太爾雜質(zhì)，孟魯司特鈉雜質(zhì)，埃博霉素B雜質(zhì)，魯比前列酮雜質(zhì)，利伐普坦雜質(zhì)，卡非佐米雜質(zhì)，夫西地酸雜質(zhì)，異舒普林雜質(zhì)，安塞曲匹雜質(zhì)，阿哌沙班雜質(zhì)，左西替利嗪雜質(zhì)，頭孢噻肟雜質(zhì)，西地那非雜質(zhì)，哌拉西林雜質(zhì)，氟哌利多雜質(zhì)，帕唑帕尼雜質(zhì)，坎格瑞洛雜質(zhì)，阿達(dá)帕林雜質(zhì)，阿塞那平雜質(zhì)，羅庫溴銨雜質(zhì)，匹杉瓊雜質(zhì)，夫羅曲坦雜質(zhì)，阿戈美拉汀雜質(zhì)，普蘆卡必利雜質(zhì)，魯格列凈雜質(zhì)，克拉霉素雜質(zhì)，吡嗪酰胺雜質(zhì)，非洛地平雜質(zhì)，青蒿琥酯雜質(zhì)，鹽酸多佐胺雜質(zhì)，替諾福韋酯雜質(zhì)，吉法酯雜質(zhì)，依佐加濱雜質(zhì)，普瑞巴林雜質(zhì)，咪達(dá)那新雜質(zhì)，瑞格列奈雜質(zhì)，米氮平雜質(zhì)，潑尼松龍雜質(zhì)，氟馬西尼雜質(zhì)，馬尼地平雜質(zhì)，溴芬酸鈉雜質(zhì)，達(dá)巴萬星雜質(zhì)，泮托拉唑雜質(zhì)，奧美拉唑雜質(zhì)，地塞米松雜質(zhì)，利奈唑胺雜質(zhì)，比卡魯胺雜質(zhì)，頭孢克洛雜質(zhì)，美洛昔康雜質(zhì)，樂卡地平雜質(zhì)，氯馬斯汀雜質(zhì)，西地那非雜質(zhì)，鹽酸瑞伐拉贊雜質(zhì)，沙芬酰胺雜質(zhì)，阿托伐他汀雜質(zhì)，替莫唑胺雜質(zhì)，沙格列汀雜質(zhì)